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Integration of Cell Line and Clinical Trial Genome-Wide
Analyses Supports a Polygenic Architecture of Paclitaxel-
Induced Sensory Peripheral Neuropathy
Heather E. Wheeler1, Eric R. Gamazon2, Claudia Wing1, Uchenna O. Njiaju1, Chidiamara Njoku1;
Robert Michael Baldwin3, Kouros Owzar4, Chen Jiang4, Dorothy Watson4, Ivo Shterev4, Michiaki Kubo5,
Hitoshi Zembutsu5, Eric P. Winer6, Clifford A. Hudis7, Lawrence N. Shulman6, Yusuke Nakamura1,5, Mark J.
Ratain1, and Deanna L. Kroetz3 for the Cancer and Leukemia Group B; Nancy J. Cox2, and Mary Eileen Dolan1
Abstract
Purpose:We sought to show the relevance of a lymphoblastoid cell line (LCL) model in the discovery of
clinically relevant genetic variants affecting chemotherapeutic response by comparing LCL genome-wide
association study (GWAS) results to clinical GWAS results.
Experimental Design: A GWAS of paclitaxel-induced cytotoxicity was conducted in 247 LCLs from the
HapMapProject and comparedwith aGWASof sensoryperipheral neuropathy inpatientswithbreast cancer
(n ¼ 855) treated with paclitaxel in the Cancer and Leukemia Group B (CALGB) 40101 trial. Significant
enrichment was assessed by permutation resampling analysis.
Results: We observed an enrichment of LCL cytotoxicity-associated single-nucleotide polymorphisms
(SNP) in the sensory peripheral neuropathy-associated SNPs from the clinical trial with concordant allelic
directions of effect (empirical P ¼ 0.007). Of the 24 SNPs that overlap between the clinical trial (P < 0.05)
and the preclinical cytotoxicity study (P < 0.001), 19 of them are expression quantitative trait loci (eQTL),
which is a significant enrichment of this functional class (empirical P ¼ 0.0447). One of these eQTLs is
located in RFX2, which encodes a member of the DNA-binding regulatory factor X family. Decreased
expression of this gene by siRNA resulted in increased sensitivity of Neuroscreen-1(NS-1; rat pheochro-
mocytoma) cells to paclitaxel as measured by reduced neurite outgrowth and increased cytotoxicity,
functionally validating the involvement of RFX2 in nerve cell response to paclitaxel.
Conclusions: The enrichment results and functional example imply that cellular models of chemo-
therapeutic toxicity may capture components of the underlying polygenic architecture of related traits in
patients. Clin Cancer Res; 19(2); 491–9. 2012 AACR.
Introduction
Paclitaxel is a tubulin-targeting agent, widely used in the
treatment of malignant disease, including ovarian, breast,
lung, and head and neck cancers. Its long-term use is often
limited by sensory peripheral neuropathy, although the
mechanism of this toxicity is poorly understood. In one
recent large study of more than 1,500 patients with breast
cancer, severe (grade 3) sensory peripheral neuropathy
occurred in 4% of patients treated with 4 cycles and 10%
of patients treated with 6 cycles of single-agent paclitaxel
(1). Currently, genetic prediction of which patients with
cancer may experience severe side effects induced by pac-
litaxel treatment is not possible (2), but several preliminary
genetic associations have beenmade (3–8). If patients likely
to experience such toxicities could be identified before
beginning a paclitaxel regimen, patient care might be
improved by implementing a reduced dose or an alternative
treatment.
Because accruing large patient cohorts receiving the same
drug regimen for discovery genome-wide and replication
studies in oncology is challenging, several groups of inves-
tigators have used lymphoblastoid cell lines (LCL) as a
discovery tool and for follow-up functional studies (9–
13). LCLs are easy to experimentally manipulate and the
genetic background and expression environment is known.
The LCLmodel also permits functional validation studies of
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candidate markers and genes discovered in both preclinical
and clinical studies (14, 15). However, a critical question is
how well this cell-based model generates clinically relevant
markers and genes associatedwith patient response to drug.
Recently, a few chemotherapeutic response single-nucleo-
tide polymorphisms (SNP) discovered in LCLs have been
replicated in patient populations by associating with phe-
notypes such as tumor response and overall survival in
patients receiving the same drug (16–19); however, these
studies tested the individual variants most associated with
the LCL phenotypes. We sought to understand to what
extent the overall genetic architecture of patient response
to chemotherapy can be captured by LCLs by investigating
beyond just the top few signals. In contrast to previous
studies that tested single SNPs, we use an enrichment
method (20) to determine in a systematic manner whether
top genome-wide association study (GWAS) SNPs for pac-
litaxel-induced sensory peripheral neuropathy in patients
with breast cancer (3) are more likely to also be paclitaxel-
induced cytotoxicity SNPs identified in LCLs than expected
by chance.
In this study, we found that SNPs associated with patient
paclitaxel-induced neuropathy are enriched for SNPs asso-
ciated with paclitaxel-induced cytotoxicity in HapMap
LCLs. This significant enrichment confirms that LCLs are
a useful model in the study of a subset of shared genes
involved in patient toxicity. The overlap SNPs are predom-
inantly expression quantitative trait loci (eQTL) as defined
previously (21), therefore supporting an enriched function-
al role for these significant SNPs. We show a functional role
for one eQTL host gene (RFX2) in paclitaxel toxicity, using a
cellular model of peripheral neuropathy. These results are
consistent with the hypothesis that the cell-based models
capture components of the underlying genetic architecture
for paclitaxel-induced sensory peripheral neuropathy.
Materials and Methods
Cytotoxicity assays
HapMap LCLs from a population with Northern and
Western European ancestry from Utah (HAPMAPPT01,
CEU, n ¼ 77), a Yoruba population in Ibadan, Nigeria
(HAPMAPPT03, YRI, n ¼ 87), and an African-American
population from the Southwest of the United States (HAP-
MAPPT07, ASW, n ¼ 83) were treated with 12.5 nmol/L
paclitaxel and cytotoxicity was determined using an Ala-
marBlue (Invitrogen) cellular growth inhibition assay as
described (22). The cytotoxicity phenotype used in the LCL
GWAS was mean percentage survival at 12.5 nmol/L pac-
litaxel determined from 6 replicates from 2 independent
experiments. Percentage survival values for each cell line
were log2-transformed before statistical analysis to form an
approximately normal distribution in each population.
LCL genome-wide meta-analysis
AGWASofpaclitaxel-induced cytotoxicitywas conducted
on each of the 3 populations separately. Greater than 2
million SNPs from HapMap r27 [minor allele frequency
(MAF) > 0.05 within the panel, no Mendelian errors and in
Hardy–Weinberg equilibrium (P > 0.001)] were tested for
association with paclitaxel cytotoxicity in each population,
using the quantitative trait disequilibrium test total associ-
ationmodel (23). To control for population structure in the
admixed ASW population, local ancestry at each genotyped
SNP locus was estimated using HAPMIX (24) and to
increase genome coverage of the ASW, ungenotyped mar-
kers were imputed using BEAGLE (25) as previously
described (26). Genomic control lambda (lGC) values
(27) were calculated for the GWAS of each population.
Studies with lGC values greater than 1 were corrected for
residual inflation of the test statistic by dividing the
observed test statistic at each SNP by the lGC (27), and
then the corresponding P values were carried through the
meta-analysis.
Using the software METAL, we combined SNP P values
across the 3 population studies, taking into account a study-
specific weight (sample size) and direction of effect (pos-
itive or negative b; ref. 28). This approach converted the
direction of effect and P value observed in each study into a
signed Z-score, such that very negative Z-scores indicate a
small P value and an allele associated with higher drug
sensitivity, whereas large positiveZ-scores indicate a small P
value and an allele associatedwith higher drug resistance.Z-
scores for each SNP were combined across studies in a
weighted sum, with weights proportional to the square-
root of the sample size for each study (28).
Patient samples and GWAS
Cancer and LeukemiaGroupB (CALGB) 40101 is a phase
III trial comparing the efficacy of standard therapy cyclo-
phosphamide and doxorubicin with single-agent paclitaxel
Translational Relevance
Lymphoblastoid cell lines (LCL) have been used in
chemotherapeutic pharmacogenomic marker discovery
due to their ease of experimental manipulation, exten-
sive genotype catalogs, and lack of the in vivo confoun-
ders present in clinical samples. One important question
is how well these cell-based models generate clinically
relevant single-nucleotide polymorphisms (SNP) asso-
ciated with patient toxicity. We compared genome-wide
association study (GWAS) results of paclitaxel-induced
cytotoxicity in LCLs and paclitaxel-induced peripheral
neuropathy in patients with breast cancer. We observed
significant overlap between the clinical and LCL studies,
thus confirming a role for the LCL model in the analysis
of at least a subset of genes involved in patient paclitaxel
response. One overlap gene, RFX2, was functionally
validated in a nerve cell model of paclitaxel response.
Peripheral neuropathy is an often dose-limiting toxicity
induced by paclitaxel treatment. If physicians could
predict which patients are more likely to experience this
severe toxicity, lower doses or alternative treatments
could be prescribed.
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as adjuvant therapy for breast cancer in women with 0 to 3
positive axillary lymph nodes. All study participants were
enrolled inCALGB40101 and gave their additional consent
to participate in the pharmacogenetic companion study
(CALGB 60202), which has been published (3). All patient
research met state, federal, and Institutional Review Board
guidelines. GermlineDNAwas isolated from1,040 patients
on the paclitaxel armof CALGB40101 and genotyped using
the Illumina 610-Quad platform as described previously
(3). Following quality control analysis, genotypes were
available for 520,679 SNPs. Principal component (PC)
analysis identified 855 genetic Europeans that were used
in a GWAS of sensory peripheral neuropathy (3). A dose-to-
event analysis was conducted, with an event defined as
grade 2 or greater sensory peripheral neuropathy. The Cox
score test, powered for additive genetic effects, was used to
test these marginal associations. Only SNPs with MAFs
more than 0.05 in the patient population and in Hardy–
Weinberg equilibrium in the CEU (P > 0.001) were used in
the LCL GWAS comparisons.
Enrichment analysis
We conducted a permutation resampling analysis (29) to
test for an enrichment of cytotoxicity-associated SNPs
(LCLs) among the paclitaxel-induced sensory peripheral
neuropathy-associated SNPs (patients). To this end, the
patient outcomes (cumulative dose and event indicator
vectors) were randomly shuffled while keeping the geno-
type data fixed to preserve linkage disequilibrium. On the
basis of this permutation replicate, the standardized Cox
score statistics were recalculated for all the SNPs. This
process was conducted 1,000 times. For each of the
1,000 permutation replicates, the number of SNPs that had
P < 0.05 in the patient data, P < 0.001 in the LCL data, and
the same direction of effect (the same allele associated with
increased neuropathy and increased cytotoxicity) was cal-
culated. The overlap distribution from the permutations
was comparedwith the observed SNPoverlap to generate an
empirical P value, calculated as the proportion of permuta-
tions in which the number of LCL/patient overlap SNPs
exceeds the observed number. To test the robustness of our
findings,we calculated an empiricalP value across a range of
inclusion thresholds from P < 0.001 to P < 0.1. We also
tested for enrichment of patient SNPs among the LCL SNPs
by generating 1,000 randomized SNP sets the same size and
MAF distribution as the observed LCL data at a range of P
value thresholds to calculate empirical P values. In addition
to the paclitaxel LCL cytotoxicity data, we compared the
patient sensory peripheral neuropathy data with LCL cyto-
toxicity GWAS data from capecitabine (30) and carboplatin
(13) as negative controls.
To test for eQTL enrichment in the LCL, patient, and LCL/
patient overlap SNPs, we generated 10,000 randomized
SNP sets each of the same size as the observed set of LCL
cytotoxicity (P < 0.001), patient neuropathy (P < 0.05), or
LCL/patient overlap SNPs. The randomized SNP sets were
matched on MAF distribution of the observed list and
sampled (without replacement) from the set of SNPs on
the Illumina 610-Quad platform, similar to the method of
Gamazon and colleagues (31). We grouped the platform
SNPs into discrete MAF bins of a width of 5%, from which
the SNPs used in the simulations were selected. For each
of the 10,000 sets, we determined the number of eQTLs
(P < 104) and calculated an empirical P value for enrich-
ment. The eQTLs were defined previously and are available
in the SCAN database (21, 31).
Filtering procedure for functional analysis
First, we determined which of the LCL/patient overlap
SNPs from the enrichment analysis were located in or near
(within 2 kb) gene transcripts (dbSNP build 129, human
genomeassembly build 36). Elevenof 24overlap SNPswere
in or near genes and genotyping intensity plots for these
SNPs in the patient data are available in Supplementary
Fig. S1. Second, we determined which SNPs within genes
were also eQTLs (31) and prioritized by which had the
most target genes (P < 104). We also tested whether the
expression of the eQTL target genes associated with pacli-
taxel-induced cytotoxicity (P < 0.05) using previously
published exon array data (32). A general linear model was
constructed between gene expression and paclitaxel-
induced cytotoxicity with growth rate (33) and population
as covariates. A Toeplitz covariance structure with 2 diag-
onal bands was used to allow for familial dependencies in
the data as previously described (9).
siRNA
Neuroscreen-1 (NS-1) rat pheochromacytoma cells (Cel-
lomics Inc.) were maintained in NS-1 media (RPMI supple-
mented with 10% horse serum, 5% fetal calf serum and 1%
L-glutamine). Cells were seeded at a density of 1 105 cells/
mL on collagen I–coated plates and induced to differentiate
by adding 20 ng/mL nerve growth factor (NGF, BD Bios-
ciences) to the media 24 hours before transfection. Cells for
cytotoxicity assays were plated in 96-well collagen I–coated
plates, whereas cells for expression quantification and neur-
ite-outgrowth assays were plated in 6-well collagen I–coated
plates. PooledRfx2 siRNA(25nmol/L;Qiagen; S101639659,
S101639666, S101639673, and S101639680) or nontarget-
ing control siRNA (Qiagen; 1027292) was transiently trans-
fected into the NS-1 cells using DharmaFECT Reagent #1
(Dharmacon). Quantitative reverse transcription PCR (qRT-
PCR) was conducted for Rfx2 (Rn00501380_m1) and con-
trol geneGapdh (4352338E) using TaqManGene Expression
Assays (Applied Biosystems) 24 hours posttransfection in
the neurite-outgrowth assays and 24, 48, 72, and 96 hours
posttransfection in the cytotoxicity assays to assess Rfx2
knockdown in NS-1 cells. Expression of the potential
Rfx2 target genes Cyp51 (Rn01526553_m1), Bach1
(Rn01477344_m1), and Cbara1 (Rn01644475_m1) was
also measured by qRT-PCR at 24 hours post-siRfx2 transfec-
tion. Each qRT-PCR was run in duplicate and individual
samples were run in triplicate on each plate. Percentage
knockdown was calculated by dividing the relative Rfx2
expression levels in the siRfx2 sample by those in the non-
targeting control sample.
Paclitaxel Cell Line and Clinical Trial Enrichment
www.aacrjournals.org Clin Cancer Res; 19(2) January 15, 2013 493
on July 12, 2019. © 2013 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst November 30, 2012; DOI: 10.1158/1078-0432.CCR-12-2618 
Neurite-outgrowth assays
Twenty-four hours following siRNA transfection, trans-
fection media was removed from the NS-1 cells and 0,
12.5, or 100 nmol/L paclitaxel in NS-1 media (supple-
mented with 20 ng/mL NGF) was added to either the
siRfx2 or nontargeting control cells. After 24 hours in
the presence of paclitaxel, phase-contrast images (10) of
the cells were taken using an Axiovert 200M inverted
widefield fluorescence microscope (Zeiss). At least 500
cells per treatment in 6 randomly chosen fields were
imaged and the longest neurite per cell was measured
using ImageJ (34) software. The entire experiment was
carried out in duplicate and mean neurite lengths were
normalized relative to the 0 nmol/L drug treatment for
each siRNA. Because tracing neurite lengths is somewhat
qualitative, 2 scientists independently measured neurite
lengths and the second scientist was blinded to siRNA/
drug treatment. The mean of each set of measurements
between the 2 scientists was assessed for significance by 2-
way ANOVA (factors: siRNA treatment and drug treat-
ment) to determine if the siRfx2 affected neurite length
upon paclitaxel treatment.
NS-1 cytotoxicity assays
Twenty-four hours after siRNA transfection, transfection
media was removed from the NS-1 cells and 0, 6.25, 12.5,
25, 50, or 100 nmol/L paclitaxel in NS-1 media (supple-
mented with 20 ng/mL NGF) in triplicate was added to
either the siRfx2or nontargeting control cells. After 72hours
of paclitaxel treatment, ATP levels were measured using the
CellTiter-Glo assay (Promega) and percentage survival
curves were generated. The entire experiment was done in
duplicate and 2-way ANOVA was used to determine if the
siRfx2 significantly affected overall cytotoxicity upon pacli-
taxel treatment.
Results
Enrichment of LCL cytotoxicity SNPs in patient sensory
peripheral neuropathy SNPs
We conducted a genome-wide meta-analysis (see Materi-
als andMethods) to test common SNPs for association with
paclitaxel-induced cytotoxicity in LCLs. We compared the
results from this analysis with those from clinical trial
CALGB 40101, a GWAS of paclitaxel-induced sensory
peripheral neuropathy in patients with breast cancer (3).
Neither study produced genome-wide significant results
(a < 0.05) nor did the very top SNPs match between the
2 studies (Fig. 1). However, through a permutation resam-
pling analysis of the CALGB patient data, we found
that the top sensory peripheral neuropathy-associated SNPs
(P < 0.05) are significantly enriched for SNPs associated
with paclitaxel-induced cytotoxicity in LCLs (P < 0.001)
with consistent allelic directions of effect (Fig. 2; empirical
P ¼ 0.007). The observed enrichment of 24 SNPs between
the LCL and patient studies is likely paclitaxel-specific, due
to the sensory peripheral neuropathy SNPs not being
enriched for either capecitabine- or carboplatin-induced
cytotoxicity SNPs, which were tested as negative controls
(Fig. 2). Positional information and effect sizes of all 24
overlap SNPs in the LCL and patient data can be found in
Supplementary Table S1.When the inclusion thresholds for
overlap SNPs were relaxed and when the LCL SNPs were
tested for enrichment of patient SNPs, the significant over-
lap was present at a range of P value thresholds from 0.001
to 0.1, showing the robustness of our findings (Supplemen-
tary Table S2).
Enrichment of eQTLs in LCL/patient overlap SNPs
We tested the top paclitaxel-induced LCL cytotoxicity
SNPs (P < 0.001) and the top paclitaxel-induced patient
sensory peripheral neuropathy SNPs (P < 0.05) for eQTL
Figure 1. Comparison of individual
GWAS results. Left, paclitaxel-
induced cytotoxicity in LCLs.
Right, paclitaxel-induced sensory
peripheral neuropathy in patients.
White lines represent the overlap
thresholds used in the primary
enrichment analysis (P < 0.001 for
LCLs and P < 0.05 for patients) and
white triangles represent the 24
overlap SNPs at these thresholds.
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enrichment because these were the thresholds used in the
primary overlap analysis. We compared the observed num-
ber of eQTLs at these thresholds to the number of eQTLs in
10,000 randomly selected MAF-matched SNP sets (for
details, see Materials and Methods). Neither cytotoxicity-
associated SNPs nor neuropathy-associated SNPs alone
were enriched for eQTLs (Fig. 3). However, we found that
the 24 paclitaxel LCL/patient overlap SNPs at these thresh-
olds are enriched for eQTLs when compared with MAF-
matched SNP sets (empirical P ¼ 0.0447), potentially
revealing an important role for this functional class in
paclitaxel toxicity.
Prioritization of LCL/patient overlap SNPs for
functional analysis
First, we determined that 11 of 24 overlap SNPs from the
enrichment analysis were located in or near (within 2 kb)
gene transcripts (Table 1). The relationship of these 11 SNPs
with paclitaxel-induced sensory peripheral neuropathy in
patients and LCL cytotoxicity is shown in Supplementary
Fig. S2. Next, we determined which of these 11 SNPs within
genes were also eQTLs (31). Of the 8 eQTLs, we determined
which had the most potential target genes at an arbitrary
threshold of P < 104. The SNP in RFX2 had 18 target genes,
more than any other of the 8 eQTLs. In addition, we tested
the expression of the target genes for association with
paclitaxel-induced cytotoxicity adjusted for growth rate (see
Materials and Methods). We found that expression of 3 of
the RFX2 target genes associated with paclitaxel-induced
cytotoxicity (Table 1 and Supplementary Table S3); there-
fore, we pursued evaluatingRFX2 in amodel of neuropathy.
Functional validation of RFX2 in a paclitaxel-induced
peripheral neuropathy model
We used neuroscreen (NS-1) cells, a subclone of the rat
pheochromocytoma cell line PC-12 that has previously
been used as a research model for chemotherapy-induced
neuropathy (35, 36), to testRfx2, the ratorthologofRFX2, for
functional involvement in paclitaxel response. Using siRNA,
we decreased expression of Rfx2 resulting in increased sen-
sitivity of NS-1 cells to paclitaxel, as measured by reduced
neurite outgrowth and increased cytotoxicity (Fig. 4). The
3 RFX2 SNP target genes whose expression associated
with paclitaxel-induced cytotoxicity in LCLs are CYP51A1,
BACH1, and CBARA1 (Table 1; Fig. 5A–C; P < 0.05). We
measured the expression of these 3 potential Rfx2 target
genes upon knockdown of Rfx2 in NS-1 cells and found that
the expression of 1 of 3 genes, Cyp51 (rat ortholog of
CYP51A1), significantly decreased 24 hours posttransfection
(P < 0.05), which is the expected direction of effect based
on the LCL expression versus cytotoxicity data (Fig. 5D).
Discussion
We conducted a GWAS of paclitaxel-induced cytotoxicity
in LCLs and showed significant enrichment of the top
cytotoxicity-associated SNPs in a clinical GWAS of paclitax-
el-induced sensory peripheral neuropathy in patients with
breast cancer. This robust enrichment shows that suscepti-
bilities to increased cytotoxicity in LCLs and sensory periph-
eral neuropathy in patients with breast cancer likely have
some genetic mechanisms in common and supports the
role of LCLs as a preclinical model for paclitaxel toxicity
studies. Furthermore, the top SNPs that overlapbetween the
2 studies were enriched for eQTLs. This eQTL enrichment
Figure 2. Patient paclitaxel-induced sensory peripheral neuropathy SNPs
are enriched for SNPs associated with paclitaxel-induced cytotoxicity in
LCLs. Distribution of chemotherapeutic-induced cytotoxicity SNP (P <
0.001) count in 1,000 permutations of neuropathy phenotype–genotype
connections (P < 0.05). The dot is the observed SNP overlap at these
thresholds. Of the 3 drug studies tested (paclitaxel, capecitabine, and
carboplatin), only paclitaxel-induced cytotoxicity SNPswere signiﬁcantly
enriched in the patient GWAS (empirical P ¼ 0.007).
Paclitaxel Cell Line and Clinical Trial Enrichment
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Figure 4. Functional validation of
RFX2 in paclitaxel response using a
peripheral neuropathy cell model.
A, representative micrographs
comparing neurite lengths of NS-1
cells upon siRNA knockdown of
Rfx2 and treatment with paclitaxel
(10 phase-contrast). B, relative
gene expression 24 hours
posttransfection in the 2 neurite
length experiments. NTC,
nontargeting control. C, decreased
expression of Rfx2 causes
decreased neurite length of
differentiating NS-1 cells (P < 104)
24 hours post-paclitaxel treatment
(48 hours posttransfection). Error
bars represent the SEM of the
longest relative neurite length of at
least 500 cells in each of 2
independent experiments. D,
relative gene expression 24 to 96
hours posttransfection in the 2
cytotoxicity experiments. E,
decreased expression of Rfx2
causes decreased survival
(increased cytotoxicity,P < 104) of
differentiatingNS-1cellsmeasured
by CellTiter-Glo 72 hours post-
paclitaxel treatment (96 hours
posttransfection). Error bars
represent the SEM of survival in 2
independent experiments with 3
replicates each.
Figure 3. SNPs associated with both patient paclitaxel-induced sensory peripheral neuropathy and LCL paclitaxel-induced cytotoxicity are enriched for
eQTLs. Distribution of eQTL (P < 104) count in 10,000 simulations, each matching the MAF distribution of either LCL paclitaxel SNPs (P < 0.001),
patient paclitaxel SNPs (P < 0.05), or the set of 24 LCL/patient overlap SNPs at these P value thresholds. Neither the LCL paclitaxel SNPs nor the patient
paclitaxel SNPs alone were enriched for eQTLs, but the overlap SNP set between the 2 GWAS was enriched for eQTLs (empirical P ¼ 0.0447).
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indicates that SNPs associated with paclitaxel-induced tox-
icity phenotypes may be functioning through gene regula-
tory mechanisms. Interestingly, neither GWAS alone was
enriched for eQTLs. Thus, our integration method may be
reducing noise and revealing important functional SNPs.
An enrichment of eQTLs has previously been shown in
SNPs associated with 6 other chemotherapeutic drugs,
which indicates that susceptibility to these drugs may
depend on subtle gene expression differences across indi-
viduals (31).
The enrichment analyses were likely affected by the
different linkage disequilibrium patterns among the popu-
lations studied. The LCL GWAS was a meta-analysis of
African, African American, and European populations,
whereas the patient GWAS was conducted in Europeans.
In the meta-analysis, SNPs that are associated with cyto-
toxicity in all populations are prioritized over those asso-
ciated in only one of the populations. We may have missed
identifying European-specific overlap alleles. However,
because the population linkage disequilibrium patterns
differ and because African populations have shorter linkage
disequilibrium blocks, overlap SNPs are more likely to be
functional SNPs rather than SNPs that simply tag a func-
tional locus (37).
We functionally assessed the involvement of one overlap
eQTL, RFX2, in the NS-1 neuropathy cell model. Paclitaxel
has previously been shown to decrease neurite outgrowth in
the parent clone of the NS-1 cell line (36). Here, we showed
that decreased expression of Rfx2 sensitizes NS-1 cells to
paclitaxel by reducing neurite outgrowth and survival. This
result validates our approach by showing that patient neu-
ropathy and LCL cytotoxicity overlap analyses can reveal
genes mechanistically involved in paclitaxel response.
Althoughmost previous work on RFX2 in mammalian cells
describes its role in spermatogenesis (38, 39), several stud-
ies point to a potential role for the protein in sensory
neurons. RFX2 and the related protein RFX1 have been
shown to directly bind and regulate the transcription of
ALMS1 (40). Mutations in ALMS1 cause the rare genetic
disorder Alstr€om syndrome, which is characterized by neu-
rosensory degeneration, metabolic defects, and cardiomy-
opathy (40). In addition, the regulatory factor X
Figure 5. Target genes of RFX2 eQTL rs7254081 in paclitaxel response.
Increased baseline expression of the rs7254081 target genes (A)
CYP51A1, (B)BACH1, and (C)CBARA1 associate with increased cellular
survival (adjusted for growth rate) of LCLs treated with 12.5 nmol/L
paclitaxel (P < 0.05). D, Rfx2 siRNA in NS-1 cells decreases the
expression ofRfx2 andCyp51, but notBach1 andCbara1, comparedwith
the nontargeting control (NTC) 24 hours posttransfection. , P < 0.05.
Error bars represent theSEMof relative gene expression in 2 independent
experiments with 3 replicates each.
Table 1. Paclitaxel-induced LCL cytotoxicity (P < 0.001) and paclitaxel-induced patient sensory peripheral
neuropathy (P < 0.05) overlap SNPs located in genes
SNP
LCL
cytotoxicity
P value
Patient sensory
peripheral
neuropathy
P value Gene eQTL
Number
of target
genes
Target genes
associated with
LCL paclitaxel-induced
cytotoxicitya (P < 0.05)
rs7254081 5.9E-04 4.8E-02 RFX2 yes 18 CYP51A1, BACH1, CBARA1
rs7642318 2.2E-04 3.9E-02 TMEM44 yes 6
rs10933663 4.0E-04 2.1E-02 TMEM44 yes 4
rs8002545 9.2E-04 3.1E-02 DIS3 yes 3
rs4782010 5.5E-04 3.5E-02 XYLT1 yes 2
rs11111539 7.9E-04 6.7E-03 C12orf42 yes 1
rs7306825 7.2E-04 9.3E-03 C12orf42 yes 1
rs8069856 1.1E-04 4.5E-02 RICH2 yes 1
rs4868011 8.2E-04 4.2E-02 KCNIP1
rs10778237 9.3E-04 1.3E-02 C12orf42
rs323285 5.1E-04 3.7E-02 KIAA1328
aAdjusted for growth rate.
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transcription factors present in Caenorhabditis elegans and
Drosophila, which are called DAF-19 and RFX, respectively,
regulate ciliated sensory neuron differentiation (41, 42).
Upon knockdown of Rfx2 in NS-1 cells, the potential
target gene Cyp51 also decreased expression, which was the
expected direction of effect based on the preliminary gene
expression analysis in LCLs. However, CYP51A1 does not
contain an X-box RFX-binding domain (43) in the promot-
er region (2 kb upstream of the transcription start site),
which means it is unlikely a direct target of RFX2 and may
instead be further downstream in the pathway. Alternative-
ly,RFX2 could be regulating an enhancer ofCYP51A1 that is
further outside the gene region.CYP51A1 is amemberof the
cytochrome P450 superfamily of enzymes, which catalyze
many reactions involved in the metabolism of drugs and
endogenous compounds. Specifically, CYP51A1 is known
to participate in the synthesis of cholesterol (44). CYP51A1
has not been previously implicated in paclitaxel metabo-
lism (45).
In the CALGB GWAS, one of the top SNPs that associated
with patient paclitaxel-induced sensory peripheral neuropa-
thy (rs10771973, P ¼ 2.6  106) is located in FGD4 (3).
Mutations in FGD4 can cause the congenital peripheral
neuropathyCharcot–Marie–Toothdisease type 4H, and thus
the gene is a plausible candidate for involvement in variation
in peripheral neuropathy induced by paclitaxel. This SNP
associationwas replicated in a second cohort of self-reported
Whitepatientswith breast cancer (n¼ 154;P¼ 0.013) and in
a cohort of self-reported African American patients with
breast cancer (n ¼ 117; P ¼ 6.7  103; ref. 3). However,
this SNP was not associated with paclitaxel-induced cytotox-
icity in LCLs (P¼ 0.65). FGD4 is not expressed in LCLs (21),
and thus the SNP is not expected to function in this model
system. While our integrative approach can reveal variants
and genes acting in paclitaxel response in both patients and
LCLs, it does not identify genes potentially acting in patients
that are not expressed in LCLs.
Effectively, LCLs have been used as an additional cohort
to study the pharmacogenomics of various chemotherapeu-
tics (16–19) because limited resources and in vivo confoun-
ders make obtaining large, homogeneous patient cohorts
difficult. Here, we saw greater SNP overlap than expected by
chance between SNPs associated with paclitaxel-induced
cytotoxicity in LCLs and SNPs associated with paclitaxel-
induced sensory peripheral neuropathy in patients at mul-
tiple P value thresholds, which confirms a role for the LCL
model in the analysis of at least a subset of genes involved in
patient neurotoxicity. This significant enrichment among a
relatively large number of top SNPs is consistent with an
underlying polygenic architecture for paclitaxel-induced
toxicity. Functional siRNA studies in the NS-1 neuropathy
model validated the involvement of RFX2 in paclitaxel
toxicity, supporting our multi-gene hypothesis. Our novel
integrative enrichment approach that combines clinical and
LCL GWAS results can be used to expand patient cohort
sizes for any drug phenotype of interest, including other
toxicities, such as neutropenia, to find genes of potential
impact that can be studied in cellular models.
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